- Sérgio Henrique Ferreira
Sérgio Henrique Ferreira (b.
April 10 ,1934 ,Franca , São Paulo),Brazil , Brazilianphysician andpharmacologist , noted for his discovery ofBradykinin potentiating factor , which led to better anti-hypertension drugs.Ferreira received his
M.D. from the Faculty of Medicine of Ribeirão Preto of the University of São Paulo (USP) and soon became staff member of the same school, where he is presently a member of the Department ofPharmacology . His research training in pharmacology initiated in this Department with Prof.Maurício Rocha e Silva , the discoverer ofbradykinin . While working on this subject, he discovered a family ofpeptide s present in the venom of a Brazilian snake, "Bothrops jararaca ", which inhibitedkininase activity and strongly potentiated the effects of bradykinin "in vivo" and "in vitro". This factor was named bradykinin potentiating factor, BPF. In 1968, with the collaboration of Dr.Lewis Joel Greene , from theBrookhaven National Laboratory , U.S., he isolated several pharmacologically active peptides responsible for the activity of BPF. Using those peptides, was demonstrated a general parallelism between bradykinin potentiation and inhibition ofAngiotensin I conversion. Subsequently, his group elucidated the structure of the smallest peptide, and using the synthetic pentapeptide, demonstrated its ability to potentiate bradykinin and to inhibit the conversion of angiotensin I in vivo in experimental models of hypertension. His work in this area paved the way for the development of a new class of antihypertensive drugs, the converting enzymes inhibitors (ACE), bySquibb scientists. For this work with theBothrops peptide he received theCIBA Award for Hypertension Research of 1983, together with Drs. E. Ondetti and D. Cushman from Squibb laboratories.While working in
London in the early seventies withJohn R. Vane (Nobel prize in Medicine, 1983), he participated in the discovery of the inhibition of the synthesis ofprostaglandins byaspirin -like drugs. At that time, he proposed that the mechanism of the analgesic action ofnonsteroidal antiinflammatory drugs (NSAID) was due to the prevention ofpain receptor sensitization which results from an inhibition of the synthesis of prostaglandins. This hypothesis was supported by further work from his laboratory and from many other investigators. His studies on the basic mechanisms involved in the development of inflammatoryhyperalgesia led to the discovery that a select class of analgesics likemetamizole , in contrast to the classical non-steroidal antiinflammatory drugs, are able to counteract the ongoing sensitization of theprimary sensory neuron via the stimulation of thearginine /nitric oxide pathway. He recently characterized a phenomenon described as retrograde sensitization of the primary sensory neuron, which emphasizes the importance of the peripheral component of the inflammatory pain. His group made a relevant contribution to the role of bradykinin and ofcytokine s in the development of inflammatory hyperalgesia. He found that among the cytokines,interleukin 1 b mediates the endogenous release of prostaglandins and IL-8 is responsible for the development of the sympathetic hyperalgesia. In this area he described an antagonist of IL-1 that is now being developed as a model a new class of analgesics.His contributions to science have been extensively recognized. Dr. Ferreira holds since 1995 the National Order of Scientific Merit in the Great Cross level, and received several awards and medals, such as from the
Third World Academy of Sciences (1990 and 1992), the Mexican Prize of Science and Technology (199), the Rheimboldt-Hauptmann Prize of the University of São Paulo (2001) and the Péter Murányi Prize (2002). He is in the editorial board of several international journals, is foreign member to the U.S. National Academy of Sciences.Dr. Ferreira is also a noted scientific leader in Brazil. He helped to found and is one of the editors-in-chief of the most influential international biomedical scientific journal,
Brazilian Journal of Medical and Biological Research , is a member of theBrazilian National Academy of Sciences and of theBrazilian Council of Science and Technology . He is founder and past president of theBrazilian Society for Pharmacology and Therapeutics and of theBrazilian Society for the Progress of Science (SBPC).Bibliography
* Ferreira, S. H. 1972. Prostaglandins, aspirin-like drugs and analgesia. "Nature New Biology". vol. 240, p. 200-203.
* Ferreira, S. H. and Nakamura, M. 1979. II-Prostaglandins hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists. "Prostaglandins". vol. 18, p. 191-200.
* Ferreira, S. H., et al. 1988. Interleukin-1b as a potent hyperalgesic agent antagonized by a tripeptide analogue. "Nature". vol. 334, p. 698-700.
* Ferreira, S. H., et al. 1991. The molecular mechanism of action of peripheral morphine analgesia: stimulation of cGMP system via nitric oxide release. "European Journal of Pharmacology". vol. 201, p. 121-122.
* Ferreira, S. H., et al. 1993. Bradykinin initiates cytokine mediated inflammatory hyperalgesia. "Brazilian Journal of Pharmacological Sciences". vol. 110, p. 1227-1231.
* Ferreira, S. H. and Lorenzetti, B. B. 1994. Glutamate spinal retrograde sensitization of primary sensory neurons associated with nociception. "Neuropharmacology". vol. 33, no. 11, p. 1479-1485.ource
* Adapted from [http://www.abc.org.br/english/orgn/acaen.asp?codigo=sferreira Sérgio Henrique Ferreira Biography] . Brazilian Academy of Sciences.
Wikimedia Foundation. 2010.